ArticleScientific reports2024
KDELR3 overexpression as a novel prognostic and diagnostic biomarker in glioma: comprehensive bioinformatic analysis insights.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Pyra-metho-carnil disrupts cancer cell proteostasis and induces apoptosis by binding to KDEL receptors.Scientific reports · 2026Article
- Identification of monotonically classifying pairs of genes for ordinal disease outcomes.Bioinformatics advances · 2026Article
- Signalling pathways and cellular functions of KDEL receptors: implications in cancer biology.Cellular and molecular life sciences : CMLS · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Glioma, the most prevalent primary intracranial malignancy among adults, is distinguished by its high morbidity and recurrence rates, posing a considerable threat to patients' quality of life and survival prospects. Consequently, the pursuit of efficacious molecular prognostic markers holds paramount importance. The exploration of the role of the KDELR3 kinase family in various neoplastic conditions constitutes an emerging area of research. However, the biological functions of KDELR3 and its prognostic implications in brain tumors remain largely undocumented. This study endeavored to ascertain the potential of KDELR3 as a prognostic indicator for glioma. We integrated a comprehensive dataset encompassing 1127 glioma samples, sourced from our cohort, The Cancer Genome Atlas (TCGA), and the Chinese Glioma Genome Atlas (CGGA), to delve into the expression patterns of KDELR3 in glioma and their associated implications. Notably, KDELR3 was markedly overexpressed in glioma and demonstrated a positive correlation with clinical progression. By utilizing Kaplan-Meier survival analysis and the Cox proportional hazards regression model, we evaluated the prognostic significance of KDELR3, revealing it as an independent predictor of adverse outcomes in glioma patients. Furthermore, gene set enrichment analysis unveiled potential signaling pathways associated with KDELR3 expression in glioma, primarily encompassing Cytokine-cytokine receptor interaction, extracellular matrix (ECM)-receptor interaction, and complement and coagulation cascades. In summation, our findings provide profound insights into the potential role of KDELR3 and its application as a novel and promising prognostic biomarker for glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.